期刊文献+

紫杉类药物在早期乳腺癌治疗中的共识和争议 被引量:5

下载PDF
导出
摘要 乳腺癌是危及女性生命的主要恶性肿瘤之一,近年来乳腺癌的死亡率已经开始下降,原因之一是有效的治疗药物越来越多.早期乳腺癌(EBC)的辅助化疗药物经历了20世纪70年代以环磷酰胺、甲氨蝶呤、氟脲嘧啶等非蒽环类为主,发展到80年代以多柔比星、表柔比星为代表的蒽环类联合化疗,90年代以紫杉醇(泰素,paclitaxel)和多西紫杉醇(多西他赛,docetaxel)为代表的紫杉类药物的问世被称为肿瘤化疗的重大突破.
出处 《实用肿瘤学杂志》 CAS 2010年第2期190-193,共4页 Practical Oncology Journal
  • 相关文献

参考文献25

  • 1Nowak AK,Wilcken NR,Stockler MR,et al.Systematic review of taxane-containing versus nontaxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer[J].Lancet Oncol,2004,5(6):372-380. 被引量:1
  • 2Bria E,Nistico C,Cuppone F,et al.Benefit of taxanes as adjuvant chemotherapy for early breast cancer:pooled analysis of 15 500 patients[J].Cancer,2006,106(11):2337-2344. 被引量:1
  • 3Ward S,Simpson E,Davis S,et al.Taxanes for the adjuvant treatment of early breast cancer:systematic review and economic evaluation[J].Health Technol Assess,2007,11(40):1-144. 被引量:1
  • 4Ferguson T,Wilcken N,Vagg R,et al.Taxanes for adjuvant treatment of early breast cancer[J].Cochrane Database of Systematic Reviews 2007,(4).Art. 被引量:1
  • 5De Laurentiis M,Giuseppe C,D′Agostino D,et al.Taxane based combinations as adjuvant chemotherapy of early breast cancer:a meta-analysis of randomized trials[J].J Clin Oncol,2008,26(1):44-53. 被引量:1
  • 6Ellis PA,Barrett-Lee PJ,Bloomeld D.Preliminary results of the UK taxotere as adjuvant chemotherapy(TACT)Trial[J].Breast Cancer Res Treat,2007,106(Suppl,abstr 78). 被引量:1
  • 7Henderson IC,Berry DA,Demetri GD,et al.Improved outcomes from adding sequential paclixaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21:976-983. 被引量:1
  • 8Mamounas EP,Bryant J,Lembersky B,et al.Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B28[J].J Clin Oncol,2005,23:3686-3696. 被引量:1
  • 9Martin M,Pienkowski T,Mackey J,et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med,2005,352:2303-2313. 被引量:1
  • 10Goldstein LJ,O′Neill A,Sparano,J.Phase III AT(doxorubicin/docetaxel)vs AC(doxorubicin/cyclophosphamide)in the adjuvant treatment of node-positive and high risk node-positive and high risk node-negative breast cancer[J].J Clin Oncol,2005,23,16s(Suppl,abstr 512). 被引量:1

同被引文献15

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部